Alcista
$117.84
Precio del escenario
$92.030
-0.479 (-0.52%)Al cierre
HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.
HealthEquity Inc appears to be a good buy right now, trading at $92.03 with a forward P/E ratio of 19.72, indicating potential for growth relative to its earnings. The gross margin has improved to 66.05% in Q2 2027, showcasing strong operational efficiency. However, the main risk is the recent insider selling trend, which has increased by 213.73% over the last quarter, indicating potential concerns among insiders about the company's future performance.
Barclays
$115
2026-09-18
Barclays
2026-09-18
Precio objetivo
$115
Deutsche Bank
$142
2026-08-31
Deutsche Bank
2026-08-31
Precio objetivo
$142
BTIG
$115
2026-07-24
BTIG
2026-07-24
Precio objetivo
$115
Citizens
$111
2026-06-01
Citizens
2026-06-01
Precio objetivo
$111
RBC Capital
$108
2026-05-29
RBC Capital
2026-05-29
Precio objetivo
$108
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

HealthEquity Reports Strong Q2 Earnings with Record Growth

HealthEquity Reports Strong Earnings but Faces Stock Sell-Off

HealthEquity Reports Strong Q2 Earnings but Stock Declines

Healthcare Stocks Decline 1.2% on NYSE

HealthEquity Announces Q2 Fiscal 2027 Earnings Release Plans
HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).
HealthEquity Inc appears to be a good buy right now, trading at $92.03 with a forward P/E ratio of 19.72, indicating potential for growth relative to its earnings. The gross margin has improved to 66.05% in Q2 2027, showcasing strong operational efficiency. However, the main risk is the recent insider selling trend, which has increased by 213.73% over the last quarter, indicating potential concerns among insiders about the company's future performance.
10 analysts cover HQY: 9 rate it Buy, 1 Hold and 0 Sell. The average price target is 117.09.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.